Zacks Investment Research Lowers Cumberland Pharmaceuticals (CPIX) to Hold

Share on StockTwits

Cumberland Pharmaceuticals (NASDAQ:CPIX) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday, reports.

According to Zacks, “Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company’s lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients. “

Separately, TheStreet raised shares of Cumberland Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, April 10th.

Shares of NASDAQ CPIX traded down $0.50 during mid-day trading on Tuesday, reaching $6.30. The company had a trading volume of 23,223 shares, compared to its average volume of 10,705. Cumberland Pharmaceuticals has a twelve month low of $4.83 and a twelve month high of $7.00. The company has a current ratio of 2.07, a quick ratio of 1.69 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $100.99 million, a PE ratio of -52.50 and a beta of 0.28.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.24. Cumberland Pharmaceuticals had a negative net margin of 10.57% and a positive return on equity of 2.54%. The business had revenue of $13.50 million for the quarter, compared to the consensus estimate of $10.98 million. As a group, analysts predict that Cumberland Pharmaceuticals will post 0.37 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlueCrest Capital Management Ltd acquired a new position in shares of Cumberland Pharmaceuticals in the first quarter worth $63,000. Renaissance Technologies LLC increased its stake in shares of Cumberland Pharmaceuticals by 2.5% in the first quarter. Renaissance Technologies LLC now owns 390,777 shares of the specialty pharmaceutical company’s stock worth $2,270,000 after acquiring an additional 9,403 shares during the last quarter. Finally, Stonepine Capital Management LLC increased its position in Cumberland Pharmaceuticals by 7.8% during the fourth quarter. Stonepine Capital Management LLC now owns 1,313,429 shares of the specialty pharmaceutical company’s stock worth $7,920,000 after buying an additional 95,028 shares during the last quarter. 32.22% of the stock is currently owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

See Also: Intrinsic Value

Get a free copy of the Zacks research report on Cumberland Pharmaceuticals (CPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with's FREE daily email newsletter.